Sonner Christine, Maa Yuh-Fun, Lee Geoffrey
Department of Pharmaceutics, Friedrich-Alexander-University, Cauerstr. 4, 91058, Erlangen, Germany.
J Pharm Sci. 2002 Oct;91(10):2122-39. doi: 10.1002/jps.10204.
This work investigates the use of spray freeze-drying (SFD) to produce protein loaded particles suitable for epidermal delivery. In the first part of the study, the effects of formulation and process conditions on particle properties are examined. Aqueous solutions of trehalose produce SFD particles in the size range 20-80 microm, with a smooth, textured surface, but having high internal porosity. The latter was visualized using SEM and a novel particle embedding and sectioning technique. Use of an annealing step during the freeze-drying cycle caused the particles to shrink, reducing hereby porosity and also the measured rate of moisture uptake into these amorphous particles. SFD pure mannitol was approximately 40% amorphous, but not hygroscopic. Incorporation of dextran 37,500 into a combined amorphous trehalose/mannitol formulation led to increased particle shrinkage and lower particle porosity on annealing. The model protein trypsinogen lost approximately 15% activity during SFD of solutions containing 50 mg/mL protein, but was only marginally aggregated (1.4%). It is suggested that trypsinogen forms an irreversible partially unfolded state or molten globule on SFD/rehydration. The pure protein was also partially inactivated without aggregation during atomization into air. Surprisingly, neither activity loss nor aggregation were detected on atomization of the protein solution into liquid nitrogen. Quench-freezing of small droplets may reverse the partial unfolding of trypsinogen occurring on atomization into air. The origin of the trypsinogen inactivation during SFD must therefore be the subsequent freeze-drying step of this multistep process. Isolated freeze drying of trypsinogen produces strong aggregation and equivalent inactivation. This result suggests that trypsinogen behaves differently during freeze drying from frozen droplets and from bulk solution in a vial. In the former case the protein forms an irreversible partially unfolded state, whereas in the latter case aggregates are formed. Trypsinogen inactivation during SFD could be completely prevented by the presence of trehalose in the formulation. Electron Spectroscopy for Chemical Analysis (ESCA) showed a high surface excess of the protein in the SFD particles, which was reduced on inclusion of Polysorbate 80, but not trehalose. Taken together, these results help to elucidate the complex destabilization behavior of trypsinogen during SFD.
本研究探讨了喷雾冷冻干燥(SFD)法制备适合表皮给药的载蛋白颗粒。在研究的第一部分,考察了配方和工艺条件对颗粒性质的影响。海藻糖水溶液制成的SFD颗粒尺寸在20 - 80微米之间,表面光滑且有纹理,但内部孔隙率较高。通过扫描电子显微镜(SEM)和一种新型的颗粒包埋与切片技术观察到了后者。在冷冻干燥循环中采用退火步骤会使颗粒收缩,从而降低孔隙率,并减少这些无定形颗粒的吸湿速率。SFD纯甘露醇约40%为无定形,但不吸湿。将37,500分子量的葡聚糖加入到海藻糖/甘露醇混合无定形配方中,会导致颗粒在退火时收缩加剧且孔隙率降低。在含有50 mg/mL蛋白质的溶液进行SFD过程中,模型蛋白胰蛋白酶原活性损失约15%,但仅轻微聚集(1.4%)。有研究表明,胰蛋白酶原在SFD/复水过程中形成了不可逆的部分展开状态或熔球态。纯蛋白在雾化到空气中时也会部分失活但不聚集。令人惊讶的是,将蛋白溶液雾化到液氮中时,未检测到活性损失和聚集现象。小液滴的骤冷冷冻可能会逆转胰蛋白酶原在雾化到空气中时发生的部分展开。因此,SFD过程中胰蛋白酶原失活的根源必定是这个多步骤过程中的后续冷冻干燥步骤。胰蛋白酶原的单独冷冻干燥会导致强烈聚集和同等程度的失活。这一结果表明,胰蛋白酶原在冷冻干燥过程中,从冷冻液滴和小瓶中的大量溶液中表现出不同的行为。在前一种情况下,蛋白质形成不可逆的部分展开状态,而在后一种情况下则形成聚集体。配方中存在海藻糖可完全防止SFD过程中胰蛋白酶原的失活。化学分析电子能谱(ESCA)显示,SFD颗粒中蛋白质的表面过量较高,加入聚山梨酯80后该值降低,但加入海藻糖后未降低。综上所述,这些结果有助于阐明胰蛋白酶原在SFD过程中复杂的失稳行为。